{"title":"Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis","authors":"","doi":"10.1016/j.cld.2024.06.014","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10489,"journal":{"name":"Clinics in liver disease","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics in liver disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S108932612400062X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
在酒精相关肝炎的初步试验中,有几种治疗方法显示出了疗效。在一项 II 期试验中,白介素-22 改善了终末期肝病模型评分和转氨酶。在美国或欧洲的一项多中心 II 期试验中,内源性胆固醇衍生物 larsucosterol 可改善疗效。抗氧化剂 N-乙酰半胱氨酸和美他多辛在大型试验中提高了存活率。印度的试验报告称,粒细胞集落刺激因子可提高存活率,接受粪便微生物群转移治疗的患者的预后也有所改善。转化研究表明,用噬菌体治疗溶胞性粪肠球菌可减轻肝损伤。
期刊介绍:
A perfect source to consult for those in the fields of gastroenterology and hepatology, Clinics in Liver Disease provides answers to clinical questions, information on the latest diagnostic methods and treatments, and numerous clinical images. Published quarterly—in February, May, August, and November—each issue offers in-depth reviews that focus on the liver and biliary system.